Current Report Filing (8-k)
July 29 2015 - 8:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
July 28, 2015
Date
of Report (Date of earliest event reported)
JAZZ
PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Ireland |
|
001-33500 |
|
98-1032470 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission
File No.) |
|
(IRS Employer
Identification No.) |
Fourth Floor, Connaught House, One Burlington Road, Dublin 4, Ireland
(Address of principal executive offices, including zip code)
011-353-1-634-7800
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On July 28, 2015, the Patent Trial and Appeal Board (the PTAB) of
the U.S. Patent and Trademark Office issued decisions instituting inter partes review (IPR) with respect to five patents related to the distribution system for Xyrem® (sodium oxybate)
oral solution. The PTAB decisions instituting review were issued in connection with petitions for IPR filed by Amneal Pharmaceuticals LLC (Amneal) and Par Pharmaceutical, Inc. (Par) in January 2015. The PTAB instituted trial on certain prior art
grounds asserted by Par and Amneal, but rejected other potential grounds for unpatentability asserted in the petitions. Jazz Pharmaceuticals Public Limited Company (the Company) expects the PTAB to issue final decisions on the validity of these
patents in approximately 12 months, and the final decisions will be appealable to the U.S. Court of Appeals for the Federal Circuit. The PTAB has not yet notified the Company whether it will institute proceedings with respect to one additional
patent related to the distribution system for Xyrem that is covered by Amneals and Pars petitions for IPR. The Company intends to disclose the PTABs decision on the sixth patent in a Quarterly Report on Form 10-Q following receipt
of such decision.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY |
|
|
By: |
|
/s/ Suzanne Sawochka Hooper |
Name: |
|
Suzanne Sawochka Hooper |
Title: |
|
Executive Vice President and General Counsel |
Date: July 29, 2015
Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From Apr 2024 to May 2024
Jazz Pharmaceuticals (NASDAQ:JAZZ)
Historical Stock Chart
From May 2023 to May 2024